GLP-1-RAs are becoming increasingly important in the treatment of cardiometabolic disorders, as shown by their inclusion in key recommendations for diabetes, CVD, and obesity management. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.